Aim: Phospholipase A2 receptor (PLA2R) is a target antigen for idiopathic membranous nephropathy (IMN). However, the association between renal PLA2R antigen and disease prognosis had not been fully investigated. In addition, there was a paucity of studies investigating the difference of therapeutic effects between cyclophosphamide and cyclosporine A in PLA2R-associated IMN.
with cyclosporine A, cyclophosphamide exerted better therapeutic effects in remission of proteinuria and may be the preferred immunosuppressant for PLA2Rassociated IMN.
K E Y W O R D S
idiopathic membranous nephropathy, phospholipase A2 receptor, prognosis evaluation, treatment options Idiopathic membranous nephropathy (IMN) is a common autoimmune glomerular disease and the primary cause of nephrotic syndrome in adults. Recently, the prevalence of IMN had dramatically increased and IMN had remained the second most common primary glomerular diseases in China. 1 In IMN patients, disease prognoses vary from spontaneous remission to progressing to end stage renal disease (ESRD). 2 Finding potential prognostic biomarkers were conducive to assessing prognosis of IMN. Phospholipase A2 receptor (PLA2R) 3 and Thrombospondin type 1 domain-containing 7A (THSD7A) 4 were recently identified as target antigens in IMN with higher specificity and sensibility. Renal PLA2R antigen deposit was detected in approximately 70% to 90% 5, 6 while the positive rate of THSD7A antigen deposition ranged from 0.7% to 9.1% in IMN patients. 4, 7 The anti-PLA2R antibody titre was found to be closely correlated with disease remission, treatment response and recrudescence. 8, 9 However, antibody titre would be easily affected by individual immune response and immunosuppressant. In the early course of the disease, PLA2R antigen will be detectable in the immune deposits by immunofluorescence staining, prior to the detection of anti-PLA2R antibodies, enable early identification of PLA2R-associated IMN. 10 Therefore, investigation on the association between renal PLA2R antigen deposit and disease prognoses would be conductive to assess prognosis of IMN.
Despite multiple controlled trials of various immunosuppressive regimens had been conducted in IMN, the optimal immunosuppressant for IMN still remain controversial. The therapeutic options of IMN should base on risk stratification, which included proteinuria, serum creatinine, estimated glomerular filtration rate (eGFR), urine IgG and PLA2R antibody levels according to recent Kidney Disease: Improving Global Outcomes controversies conference. 11 For the IMN patients at high risk of progression, immunosuppressive agents should be initiated early. Alkylating agents are recommended to be initial therapy in IMN and remain the only agents proven effective in preventing renal function progression. 12 As the main alkylating agents, cyclophosphamide (CTX) could inhibit lymphocyte proliferation, rapidly depleting B and T cells and further suppressing humoral and cellular immunity. 13 Cyclosporine A (CsA) is an alternative regimen for the initial therapy of IMN, with a comparable remission rate compared with CTX. 14 CsA have been demonstrated to suppress T cell responses through calcineurin-phosphatase pathway and the nuclear translocation of nuclear factor of activated T-cells (NFAT). 15, 16 However, in PLA2R-associated IMN, the difference of therapeutic effects between CTX and CsA had not been investigated. Therefore, the objective of this study was to investigate the prognostic value of renal PLA2R antigen deposit and to compare the difference of therapeutic effects between CTX and CsA in PLA2R-associated IMN. 
| Definitions
According to renal PLA2R immunohistochemistry, IMN was categorized into PLA2R-associated and non-PLA2R-associated IMN. We used the formula of the Chronic Kidney Disease Epidemiology Collaboration to calculate the eGFR. Glomerular haematuria was defined as urinary red blood cell (RBC) greater than 8000/mL and dysmorphic RBC accounted for greater than 75% of the total number of RBC. 17 Complete remission was defined as urinary protein excretion<0.3 g/ day, accompanied by a normal serum albumin (ALB) and a normal Scr.
Partial remission was defined as urinary protein excretion <3.5 g/day and a 50% or greater reduction from peak values, accompanied by an improvement or normalization of serum ALB and stable Scr. 18 The presence of complete remission or partial remission was all defined as remission. Spontaneous remission was defined as protein-uria<3.5 g/24 hours and at least 50% reduction from the time of initiating conservative treatment. 19 The end point of renal survival was defined as a 50% decline in eGFR or double of serum creatine or progression to ESRD with eGFR < 15 mL/min/1.73 m 2 compared with baseline. ELISA provided quantitative results for the determination of anti-PLA2R antibodies and a negative antibody titre was defined as an anti-PLA2R antibody titre <14 RU/mL. MN was graded into four stages according to the Ehrenreich and Churg's classification criteria. 20 Tubular atrophy/interstitial fibrosis was graded as absent (T0), mild (T1) <25%, moderate (T2) 25%-50% or severe (T3) >50%. 21 IgG4 dominant deposition was defined as stronger deposition of IgG4 subgroup than IgG1, IgG2 and IgG3 subgroup.
| Detection of renal PLA2R antigen deposits
Renal PLA2R antigen deposits in IMN patients were detected by indirect immunofluorescence in frozen sections. Renal biopsy tissues were cut was used as the primary antibody and incubated for 1 hours. After the slides were rinsed with PBS for twice, fluorescein isothiocyanate labelled mouse anti-rabbit IgG antibody (Dako, 1:100 dilution) was used as secondary antibody. Incubation was carried out at 37 C for 40 minutes.
The slides were dried and sealed with glycerin for observation under fluorescence microscope. PLA2R staining was defined as positive with granular staining along the glomerular capillary wall in the glomeruli.
| Statistical analyses
All data were analyzed using statistical product and service solutions (SPSS) statistical software for Windows, version 23.0 (SPSS, Inc., Chicago, Illinois). The measurement data accorded with normal distribution were expressed as mean ± SD and differences between two groups were compared using student t test. The non-normally distributed data were expressed as medians (25th, 75th percentiles) and differences between two groups were compared using non-parametric No patients were treated with anti-CD20 monoclonal antibody.
There was no significant difference in the proportion of therapeutic regimen between PLA2R-associated and non-PLA2R-associated IMN. The median follow-up time of PLA2R-associated and non-PLA2R-associated IMN patients were both 12 months and had no statistical difference between two groups ( Table 1) 
| Association between renal PLA2R antigen and proteinuria remission
Among 300 IMN patients enrolled for prognostic analysis, Kaplan-Meier analysis showed that non-PLA2R-associated IMN patients had a higher probability to achieve remission than PLA2R-associated IMN patients (Log-rank test, P = .013) ( Figure 2 Note: HR was adjusted for positive renal PLA2R antigen, eGFR, serum albumin, proteinuria and immunosuppressive therapy. The variables were selected into the multivariate COX analysis in an "Enter" manner. Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; PLA2R-GAg, glomerular PLA2R antigen.
higher level of proteinuria (HR: 1.680; 95% CI: 1.123 to 2.511; P = .011) were independent risk factors for not achieving remission in IMN patients (Table 2 ).
| Association between renal PLA2R antigen and spontaneous remission
Among 300 IMN patients, 82 (27.3%) patients received conservative therapy without using immunosuppressive agents or corticosteroids during follow up. Kaplan-Meier analysis showed that non-PLA2Rassociated IMN patients had a higher probability to achieve spontaneous remission than PLA2R-associated IMN patients (Log-rank test, P = .012) ( Figure 3 ). Univariate COX regression analysis showed that positive renal PLA2R antigen was risk factor for not achieving sponta- 64 41 27 12 10 6  3  3  1   13 13 12  4  3  3  3  3  3  3  1 Log-rank p=0.012 F I G U R E 3 Kaplan-Meier analysis of spontaneous remission in patients with positive and negative phospholipase A2 receptor (PLA2R) antigen deposit. The numbers of at-risk patients at selected time points (3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 months) were indicated below the plot. Log-rank method was used to evaluate the significance of differences serum albumin and proteinuria, positive renal PLA2R antigen was still an independent risk factor for not achieving spontaneous remission in IMN patients (HR: 2.927; 95% CI: 1.270 to 6.743; P = .012) ( Table 3 ). Figure 4A ). However, there was no significant difference in renal survival between CTX and CsA groups (Log-rank test, P = .075) ( Figure 4B ). Univariate COX regression analysis showed that compared with CTX, CsA had a lower probability to achieve remission (HR: 1.851; 95% CI: 1.148 to 2.982; P = .011). After adjusting for proteinuria, serum albumin and eGFR at baseline, patients receiving CTX still had a higher probability to achieve remission compared with those receiving CsA (HR: 1.933; 95% CI: 1.123 to 3.325; P = .017) ( Table 4 ).
| Therapeutic difference between CTX and

| DISCUSSION
Idiopathic membranous nephropathy is autoantigen-mediated autoimmune glomerular disease. Renal PLA2R antigen had been identified to be target antigen with higher specificity and sensitivity in IMN. 3 Several studies had found that serum anti-PLA2R antibodies were correlated with IMN prognosis. 8, 9 Early in the course of the disease, circulating anti-PLA2R antibodies might not be detectable despite their presence in the glomerular deposits, because the kidney acts as a "sink" absorbing all detectable circulating anti-PLA2R antibodies. 10 Therefore, the detection of renal PLA2R antigen deposit would provide early evidence of PLA2R-associated IMN. In addition, along with the remission of proteinuria, anti-PLA2R antibodies would disappear from the circulation while renal PLA2R antigen, with a slow attenuation, would be detectable continuously. Therefore, renal PLA2R antigen deposit is more stable than circulating anti-PLA2R antibodies in different course of disease. We conducted this retrospective cohort to explore the clinicopathological characteristics of PLA2R-associated IMN and the association between renal PLA2R antigen deposit and remission of proteinuria.
In this retrospective cohort study, 82.3% of patients with IMN had positive renal PLA2R deposits, which was comparable to previous researches. 22, 23 By comparing the clinical and pathological characteristics between PLA2R-associated and non-PLA2R-associated IMN patients, we found that patients with positive renal PLA2R antigen showed a lower level of serum albumin and a higher level of anti-PLA2R antibody. Previous study 24 We further explored the association between renal PLA2R antigen and the remission of proteinuria in IMN. Our findings suggested that non-PLA2R-associated IMN patients had a higher probability to achieve remission than PLA2R-associated IMN patients after adjusting for confounders. This result was consistent with previous reports. A retrospective study included 572 IMN patients had found that patients who did not achieve remission had a higher positive rate of renal PLA2R antigen than those achieved remission. 25 Another retrospective cohort study had also identified a higher remission rate in non-PLA2R-associated IMN. 26 The reason for lower probability to achieve remission in PLA2R-associated IMN patients still remained unclear. Autoantibody may target a specific conformational region of PLA2R protein on the podocyte surface and trigger the formation of immune complexes, which may lead to the activation of complement pathway and the enhancement of glomerular permeability to plasma proteins. Moreover, for those received conservative therapy alone without using immunosuppressive agents, patients with negative renal PLA2R antigen deposit at diagnosis had a higher probability of progressing towards spontaneous remission. Therefore, renal PLA2R antigen could be identified as evaluation indicator for initiating immunosuppressive therapy. Non-PLA2R-associated IMN patients were recommended to prolong the duration of conservative therapy on account of its high probability to achieve spontaneous remission compared with PLA2R-associated IMN.
The second point of our study was to investigate the therapeutic prognosis between two immunosuppressant regimens in PLA2Rassociated IMN. Both CTX and CsA were the first line initial immunosuppressive therapy protocol for IMN, with similar remission rate according to previous findings. 14 
